
IBM Stock: Stable Dividend or Stagnant Investment?
The AI race has heated up significantly but returns on…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Income Statement | ||||||
Revenue | $1B | $1.8B | $2.2B | $439.7M | $593.2M | |
Gross Profit | $868.6M | $1.5B | $1.9B | $353.9M | $490.3M | |
Operating Income | -$785.1M | -$282.2M | -$176.9M | -$116.4M | -$105.2M | |
EBITDA | -$910.4M | -$239.2M | -$158.3M | -$106.3M | -$155M | |
Diluted EPS | -$9.29 | -$3.56 | -$2.17 | -$1.10 | -$0.65 |
Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $2.6B | $2.8B | $2.7B | $3B | $3.3B | |
Total Assets | $3.4B | $3.6B | $3.5B | $3.8B | $4.2B | |
Current Liabilities | $585.3M | $695.7M | $767.9M | $967.8M | $1.2B | |
Total Liabilities | $2.4B | $3.1B | $3.7B | $4.1B | $4.2B | |
Total Equity | $1B | $588.2M | -$158.2M | -$220.6M | $67.1M | |
Total Debt | $191.3M | $675.7M | $1B | $1B | $1B |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Cash Flow Statement | ||||||
Cash Flow Operations | -$541.3M | $104.2M | -$8.3M | -$29.8M | -$94.7M | |
Cash From Investing | $169.4M | -$336.4M | -$116.8M | -$240.7M | -$52.9M | |
Cash From Financing | $425.8M | $172.1M | $294.2M | $39.2M | $31M | |
Free Cash Flow | -$613.3M | $41.9M | -$42.6M | -$45.1M | -$103.8M |
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
In the current month, ALNY has received 11 Buy ratings 9 Hold ratings, and 1 Sell ratings. The ALNY average analyst price target in the past 3 months is $304.61.
According to analysts, the consensus estimate is that Alnylam Pharmaceuticals share price will rise to $304.61 per share over the next 12 months.
Analysts are divided on their view about Alnylam Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alnylam Pharmaceuticals is a Sell and believe this share price will drop from its current level to $195.00.
The price target for Alnylam Pharmaceuticals over the next 1-year time period is forecast to be $304.61 according to 21 Wall Street analysts, 11 of them rate the stock a Buy, 1 rates the stock a Sell, and 9 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Alnylam Pharmaceuticals is a Buy. 11 of 21 analysts rate the stock a Buy at this time.
You can purchase shares of Alnylam Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alnylam Pharmaceuticals shares.
Alnylam Pharmaceuticals was last trading at $233.10 per share. This represents the most recent stock quote for Alnylam Pharmaceuticals. Yesterday, Alnylam Pharmaceuticals closed at $244.52 per share.
In order to purchase Alnylam Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
The AI race has heated up significantly but returns on…
Trimble (NASDAQ:TRMB) is a hardware and software tech company that…
It seems like right now is a good time to…
Market Cap: $3.6T
P/E Ratio: 39x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.6T
P/E Ratio: 36x
Willdan Group [WLDN] is down 3.66% over the past day.
Pro-Dex [PDEX] is up 10.33% over the past day.
Samsara [IOT] is down 3.68% over the past day.